Lupin is currently trading at Rs. 775.70, up by 9.60 points or 1.25% from its previous closing of Rs. 766.10 on the BSE.
The scrip opened at Rs. 769.90 and has touched a high and low of Rs. 782.80 and Rs. 759.05 respectively. So far 89268 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.
Last one week high and low of the scrip stood at Rs. 782.80 and Rs. 720.40 respectively. The current market cap of the company is Rs. 35170.07 crore.
The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.
Lupin has received Establishment Inspection Report (EIR) from USFDA for its Pithampur (Unit-3) facility in Indore in the state of Madhya Pradesh. The inspection was conducted between October 8, 2018 to October 18, 2018. Lupin’s Pithampur Unit-3 is involved in the manufacture of Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Topical Formulations for the regulated markets.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
